Phase­Bio claims pos­i­tive PhII in platelet in­hi­bi­tion re­ver­sal; Tri­al soft­ware firm re­brands af­ter hack, merg­er

Aim­ing to bring new car­diopul­monary drugs to mar­ket, Phase­Bio took one step clos­er to­ward that goal Wednes­day morn­ing.

The biotech re­port­ed pos­i­tive topline re­sults for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER